AIHealthcare

Caris Life Sciences is an Irving, Texas–based precision oncology and AI TechBio company that develops molecular profiling, cancer diagnostic, therapy-selection, clinical-trial, and biopharmaceutical research solutions. Its technology combines whole-exome, whole-transcriptome, whole-genome, protein, and clinical-outcomes data with artificial intelligence and machine learning. The company operates a large multimodal clinico-genomic database and applies proprietary tools including CODEai, GPSai, and FOLFIRSTai to support cancer classification, treatment-response prediction, biomarker discovery, drug development, and clinical research. Caris has reported testing more than one million patient cases and describes itself as a U.S. market leader in tissue genomic profiling; this market-position claim is company-reported and has not been independently verified here. Caris became a publicly traded company on Nasdaq under the symbol CAI in June 2025.